A New Drug For Weight Management

Obesity remains an extremely serious issue worldwide. Once considered a problem for wealthier counties, overweight and obesity are now dramatically increasing in low and middle income countries (WHO, 2011). In American, the rates of obesity continue to soar. CDC (2009) recognizes obesity as a risk factor for diabetes, heart disease, high blood pressure, and other health problems. According to NHANES over two-thirds of the US are overweight or obese, and over one-third are obese (CDC, 2009). Treatment for this illness varies; it may include the incorporation of diet, exercise, behavior modification, medication, and surgery. Since there is no single cause of all overweight and obesity, there is no single way to prevent or treat overweight

In regards to proper nutrition, a diet that has a low glycemic index has been found to improve blood sugar control. Unfortunately, diet and exercise aren’t enough to achieve glycemic control for some individuals. At this time, medication is usually introduced to the treatment regimen. Oral medications such as Metformin, sulfonylureas, nonsulonylurea secretagogues, alpha glucosidase inhibitors and thiazolidinediones are available. However, Metformin is usually the first line of treatment. In some patients, insulin can be added to their medication regimen. Consequently, in cases where the individual is morbidly obese and lifestyle modifications with medication therapy prove to be ineffective in maintaining glycemic control, weight loss surgery can be considered (Polonsky, 2014).

This research is performed after preliminary evidence suggesting effectiveness of the drug has been obtained. The intention of this research is to gather additional information with regard to effectiveness and safety and attempts to be conclusive with answers about the drug as far as benefit/risk issues are concerned. This is also the phase in the drug research process where labels are created and the basic guidelines for definition and public informative information is finalized. These studies may include several hundred to several thousand people.

of the study is to determine the benefits and safety of the drug called Liraglutide in patients with

These types of statistics, portraying the growth of diabetes diagnoses, have driven researchers and physicians to find diets, medications, and preventive measures for the disease. In reviewing the medications that are used to treat diabetes, their sometimes-severe complications should be noted. What’s more, none of them speak to the actual, principal source of developing diabetes. Therefore, research on preventive measures and diets have become popular.

calculate weight-based medications for the obese patient. The patient’s ideal body weight is subtracted from the patient’s actual weight and multiplied by 0.4. Incorporating the obese patients BMI may also be beneficial to more effective weight-based medication dosing despite not being traditionally used to dose medications. More hospitals are utilizing pharmacists with dosing weight based medications using the best known modifications for the elderly and obese. Pharmacists use drug blood levels to dose most appropriately for each individual patient. Additional research is needed to find to most accurate means to calculate weight-based medications for the obese patient as dosing is more complex and results in longer hospitalization.

It has three sites involved in appetite regulation ventromendial nucleus, lateral hypothalamus and arcuate nucleus. Through studies using mice, lesions to the hypothalamus has resulted in hyperphagia or hypophagia. In human studies, patients with tumors in the hypothalamus have been shown to be hyperphagia or hypophagia. The regulation of food intake is a complicated process. It involves external factors and signals from certain hormones through the hypothalamus. These factors act as appetite stimulator and appetite suppressors to control energy intake and expenditure. There have been several weight loss drugs developed to treat obesity. Three of the drugs are orlistat, sibutramine, and rimonabant. Orlistat prevents fat digestions and absorption by binding to gastrointestinal lipases. The fat is blocked and fat is not digested and passed out in feces. Sibutramine works differently to affect the nerve cells in the brain that regulate appetite. Rimonabant works as a CB1 antagonist. The drug binds to a receptor without activating it and preventing endocannabinoid to bind to it which decreases cell signals for appetite. The desire is for less appetite. A person will gain weight once stopping the drugs and limited in there use for weight loss. Weight loss surgery is used to limit the amount of intake of foods by decreasing the size of the stomach. The options are the duodenal switch, gastric binding, sleeve gastrectomy and gastric

In COMBO group, patients received metformin (initiated at 500 mg by mouth once daily and increased to 1000 mg twice daily) and liraglutide (started at 0.6 mg inject subcutaneous once daily and increased to 1.2 mg once daily). On the other hand, in LIRA3 group, liraglutide was started at 0.6 mg injected subcutaneous once daily and increased up to 3 mg daily. Therefore, the primary outcome was focused on the mean change in anthropometric measures (heights, weight, and waist circumference) of obesity. Besides, the secondary outcomes were based on metabolic and hormonal changes.6

It was merely a decade ago that the obesity epidemic was thought to only be a minor problem and had only alarmed a small number of endocrinologists interested by the size of the situation (James, 2008). However today, the problem of obesity is vast with more awareness of its presence by doctors and individuals alike. In fact, the Center for Disease Control and Prevention states, “More than one-third (34.9% or 78.6 million) of U.S. adults are obese (CDC, 2014)”. These numbers are outrageous and eye opening, leaving millions looking for a solution to this troubling epidemic. Obesity is not simply a cosmetic flaw as some might think, but is actually a very dangerous state of being for any individual to sustain long-term. Mentioned further in

In June 2012, the U.S Food and Drug Administration approved marketing of the weight reduction drug Belviq (Lorcaserin hydrochloride), but the same drug application was formally rejected by the European Medicine Agency (EMA) by claiming that “the benefits of Belviq did not outweigh its risks” (Wolfe, 2013). While, I believe that Belviq have proven to be safe and effective in reducing weight in particular group of population, I strongly disagree with its market approval by knowing the fact that the potential benefits of Belviq do not outweigh the potential risks associated with its long term use in overweight and obese individuals.

Patients who took 3.4 grams every day over a period of 2 months showed a statistically significant decrease in body fat. Moreover, these results also show that besides reducing the amount of body fat, conjugated linoleic acid also preserves the amount of muscle in the body. This is especially important because during weight loss diets, most of the energy is made from proteins, instead of fat.

The each new weight reduction mark showing up available today appears to partition individuals into two segments: the individuals why should prepared attempt it promptly and the individuals who considers, "God help us, not another pills, 'cause they are all pointless". This year has seen the showing up of over-the-stabilizer misfortune pills with solid logical proofs and authority endorsements. What's more, these weight reduction pills seemed to blend the best sides of understood sorts of physician endorsed medications and weight reduction supplements.

A lifestyle drug is a drug that is not primarily the fight against a disease , but the improvement in physical fitness or general well-being used. Lifestyle Medicine designates primarily medical methods that store a certain lifestyle. The lifestyle is particularly determined by the self-understanding of a man. Medicine that is taken preventively in the first place and to improve the living conditions such as supplements for weight loss or overcome sexual dysfunction. Whatever one may think about this: The consumption of alcohol, tobacco and illicit drugs is an everyday reality. They are consumed, although the associated health risks are known. With a congenital heart defect the dangers of consuming, however, are even greater.

Obesity is one of the most common problems faced by people today. Since thirty-four million Americans are estimated to be obese, one out of every three Americans must live with this disorder. Obesity is defined as a body weight consisting of 20% or more above the standard ideal weight (http://www-med.stanford.edu/school/DGIM/Teaching/Modules/obesity.html#RTFToC12). In order to reduce obesity, most invest in diet and exercise programs. Recently, liquid diets have been positively modified, thus rising in popularity since their fall out during the late 1970’s. Out of the twenty million dieters, about one billion dollars will be spent this year on either medically sponsored liquid diets or over-the-counter liquid diet

Medibical is the first FDA-approved prescription drug for the overweight segment (BMI 25-30). It is a low-dose formula that reduces stress on heart and liver functions. Metabical also contains a controlled-release feature that requires only one pill be taken per day which leads to better patient compliance. Participants experience dramatic weight loss with an average 26 pounds for BMI 28-30 and 15 pounds for BMI 25-28 within 12 weeks. There are also less severe negative side effects associated with excess fat and calories in the diet which can help with behavior modification and promote healthier eating habits. CSP also plans to create a comprehensive